Clinical Trials
23 trialsNCT04748419 2026-06-05
Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab
University of Nebraska
Phase 1/2 Terminated
NCT06498635 2026-06-03
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT04092283 2026-05-29
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05198830 2026-05-27
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05061550 2026-05-22
NeoCOAST-2
AstraZeneca
Phase 2 Recruiting
NCT06287775 2026-05-22
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT07603856 2026-05-22
REVIVE
University of Chicago
Phase 2 Not yet recruiting
NCT04380636 2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06606847 2026-05-15
LADOGA
AstraZeneca
Phase 2 Active not recruiting
NCT05374603 2026-05-14
SOUND
AstraZeneca
Phase 2 Active not recruiting
NCT06732401 2026-05-13
CLEAR
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04716946 2026-05-11
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05092412 2026-05-08
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Phase 2 Active not recruiting
NCT05624996 2026-05-04
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NRG Oncology
Phase 3 Recruiting
NCT04902040 2026-04-30
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02664935 2026-04-28
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Completed
NCT03833154 2026-04-23
PACIFIC-4
AstraZeneca
Phase 3 Active not recruiting
NCT07339059 2026-04-23
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
NCT05450692 2026-04-16
LATIFY
AstraZeneca
Phase 3 Active not recruiting
NCT07288034 2026-04-15
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Phase 2 Recruiting
NCT03589547 2026-04-02
358
Brown University
Phase 2 Completed
NCT03923270 2026-04-01
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT04499053 2026-03-16
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Georgetown University
Phase 2 Recruiting